A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease (Autonomy)
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study With a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease
The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognition and function.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Adelaide, Australia, 5000
- Royal Adelaide Hospital
-
Box Hill, Australia, 3128
- Box Hill Hospital
-
Carlton, Australia, 3053
- Neuro Trials Victoria
-
Ivanhoe, Australia, 3079
- Austin Health
-
Malvern, Australia, 3144
- HammondCare Neurodegenerative Clinical Trials - VIC
-
Nedlands, Australia, 6009
- Australian Alzheimer's Research Foundation Incorporated
-
Parkville, Australia, 3050
- Royal Melbourne Hospital
-
-
-
-
-
Bruges, Belgium, 8000
- AZ St.-Jan Brugge-Oostende AV
-
Brussels, Belgium, 1200
- UCL Hopital Saint-Luc
-
Edegem, Belgium, 2650
- UZ Antwerpen
-
Ghent, Belgium, 9000
- Universitair Ziekenhuis Gent
-
Hasselt, Belgium, 3500
- Jessa Ziekenhuis
-
Jette, Belgium, 1090
- UZ Brussel
-
Leuven, Belgium, 3000
- UZ Leuven
-
Roeselare, Belgium, 8800
- Algemeen Ziekenhuis Delta
-
-
-
-
Ontario
-
London, Ontario, Canada, N6C 0A7
- Parkwood Institute
-
Peterborough, Ontario, Canada, K9H 2P4
- Kawartha Centre - Redefining Healthy Aging
-
Toronto, Ontario, Canada, M3B 257
- Toronto Memory Program (Neurology Research Inc.)
-
Toronto, Ontario, Canada, M5T 2S8
- UHN-Toronto Western Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 2B4
- McGill University
-
-
-
-
-
Bordeaux, France, 33076
- Hopital Pellegrin CHU Bordeaux
-
Lille, France, 59037
- Hopital Roger Salengro - CHU Lille
-
Nantes, France, 44093
- CHU Nantes - Hopital Nord Laënnec
-
Paris, France, 75010
- Hopital Lariboisiere-Fernand Widal
-
Paris, France, 75013
- Hopital Pitie Salpetriere
-
Rennes, France, 35009
- Chu Rennes Hopital Pontchaillou
-
Rouen, France, 76031
- Hopital Charles Nicolle
-
Toulouse, France, 31059
- CHU Toulouse - Hôpital La Grave
-
Tours, France, 37000
- Hôpital Bretonneau
-
-
-
-
-
Aizu-Wakamatsu, Japan, 965-8585
- Takeda General Hospital
-
Chiba, Japan, 263-0043
- Inage Neurology and Memory Clinic
-
Fujisawa-shi, Japan, 251-0038
- Kawashima Neurology Clinic
-
Fukuoka, Japan, 814-0180
- Fukuoka University Hospital
-
Hachiōji, Japan, 192-0071
- Keikokai P-One Clinic
-
Himeji, Japan, 672-8043
- Himeji Central Hospital Clinic
-
Kamakura-shi, Japan, 247-8533
- Shonan Kamakura General Hospital
-
Kanzaki-gun, Japan, 842-0192
- National Hospital Organization Hizen Psychiatric Center
-
Kawasaki, Japan, 210-0852
- Koukan Clinic
-
Kobe, Japan, 650-0047
- Kobe City Medical Center General Hospital
-
Kurashiki-shi, Japan, 7100813
- Rijikai Medical Corporation Katayama Medical Clinic
-
Kurume, Japan, 830-0011
- Kurume University Hospital
-
Kyoto, Japan, 607-8062
- Rakuwakai Otowa Hospital
-
Kyoto, Japan, 607-8113
- Rakuwakai Otowa Rehabilitation Hospital
-
Narashino, Japan, 275-0006
- Saiseikai Narashino Hospital
-
Obu-shi, Japan, 474-8511
- National Center For Geriatrics And Gerontology
-
Shinjuku-ku, Japan, 162-0053
- Clinical Research Hospital Tokyo
-
Tokyo, Japan, 160-0023
- Tokyo Medical University Hospital
-
Tokyo, Japan, 173-0015
- Tokyo Metropolitan Geriatric Hospital
-
Toyonaka-shi, Japan, 560-0004
- Nagomi Clinic
-
Toyonaka-shi, Japan, 5600004
- Jinsenkai MI Clinic
-
Yokohama, Japan, 235-0012
- Yokohama Brain and Spine Center
-
-
-
-
-
's-Hertogenbosch, Netherlands, 5223 LA
- BRC - Den Bosch
-
Amsterdam, Netherlands, 1081 GN
- BRC - Amsterdam
-
Leeuwarden, Netherlands, 8934AD
- QPS Netherlands
-
Zwolle, Netherlands, 8052 AZ
- BRC Zwolle
-
-
-
-
-
Algorta - Getxo, Spain, 48993
- Centro At. Esp. Oroitu
-
Barcelona, Spain, 08025
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona, Spain, 08003
- Hosp. Del Mar
-
Barcelona, Spain, 08028
- Fund. Ace-Inst. Cat. Neuroc. Aplicades
-
Barcelona, Spain, 08195
- Idc Salud Hosp. Gral. de Catalunya
-
Lleida, Spain, 25198
- Hosp. Univ. Santa Maria
-
Madrid, Spain, 28040
- Hosp. Clinico San Carlos
-
Terrassa, Spain, 08221
- Hosp. Mutua Terrassa
-
Valencia, Spain, 46026
- Hosp. Univ. I Politecni La Fe
-
-
-
-
-
Stockholm, Sweden, 14186
- Karolinska Universitetssjukhuset
-
-
-
-
-
Bath, United Kingdom, BA1 3NG
- Royal United Hospital
-
London, United Kingdom, W6 8RF
- Charing Cross Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama Birmingham
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
- Dignity Health
-
-
California
-
Irvine, California, United States, 92614
- Irvine Clinical Research
-
La Jolla, California, United States, 92037
- University of California San Diego Medical Center
-
Los Angeles, California, United States, 90095
- University of California - Los Angeles
-
Palo Alto, California, United States, 94304
- Stanford University Medical Center
-
San Diego, California, United States, 92103
- Pacific Research Network Prn
-
Santa Ana, California, United States, 92705
- Syrentis Clinical Research
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale University School Of Medicine
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20007
- Georgetown University Clinical Research Unit CRU
-
-
Florida
-
Atlantis, Florida, United States, 33462
- JEM Research LLC
-
Delray Beach, Florida, United States, 33445
- Brain Matters Research
-
Fort Myers, Florida, United States, 33912
- Neuropsychiatric Research Center of SWFL
-
Jacksonville, Florida, United States, 32256
- Clinical NeuroScience Solutions Inc
-
Jupiter, Florida, United States, 33458
- Alphab Global Research
-
Maitland, Florida, United States, 32751
- K2 Medical Research
-
Maitland, Florida, United States, 32751
- Tandem Intermediate LLC
-
Merritt Island, Florida, United States, 32952
- Merritt Island Medical Research, LLC
-
Miami, Florida, United States, 33136
- University of Miami Miller School of Medicine
-
Miami, Florida, United States, 33137
- Miami Jewish Health System
-
Naples, Florida, United States, 34105
- Aqualane Clinical Research
-
Ocala, Florida, United States, 34470
- Renstar Medical Research
-
Ocoee, Florida, United States, 34761
- Sensible Healthcare
-
Tampa, Florida, United States, 33609
- Axiom Clinical Research of Florida
-
Tampa, Florida, United States, 33613
- Stedman Clinical Trials
-
Tampa, Florida, United States, 33613
- University of South Florida - Health Byrd Alzheimer Institute
-
The Villages, Florida, United States, 32162
- Charter Research
-
Viera, Florida, United States, 32904
- ClinCloud Clinical Research
-
Wellington, Florida, United States, 33414
- Alzheimers Research and Treatment Center
-
West Palm Beach, Florida, United States, 33407
- Palm Beach Neurology and Premier Research Institute
-
Winter Park, Florida, United States, 32789
- Conquest Research
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- The Emory Clinic
-
Decatur, Georgia, United States, 30030
- Sandhill Research
-
-
Illinois
-
Chicago, Illinois, United States, 60640
- Great Lakes Clinical Trials
-
Elk Grove Village, Illinois, United States, 60007
- Alexian Brothers Medical Center - Neuroscience Research Institute
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Braintree, Massachusetts, United States, 02184
- Anil Nair dba Alzheimer's Disease Center
-
-
Mississippi
-
Hattiesburg, Mississippi, United States, 39401
- Hattiesburg Clinic
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Washington University School Of Medicine
-
-
New Jersey
-
Mount Arlington, New Jersey, United States, 07856
- NeuroCognitive Institute
-
Princeton, New Jersey, United States, 08540
- Princeton Medical Institute
-
Toms River, New Jersey, United States, 08755
- Advanced Memory Research Institute of NJ
-
-
New York
-
Albany, New York, United States, 12208
- Neurological Associates of Albany, PC
-
East Syracuse, New York, United States, 13057
- Velocity Clinical Research
-
New York, New York, United States, 10016
- New York University Medical Center
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Health Sciences
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Lou Revo Center for Brain Health
-
Columbus, Ohio, United States, 43221
- Wexner Medical Center at the Ohio State University
-
-
Pennsylvania
-
Plymouth Meeting, Pennsylvania, United States, 19462
- Keystone Clinical Studies LLC
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02906
- Brown University School of Medicine
-
-
Texas
-
Houston, Texas, United States, 77054
- The University of Texas Health Science Center at Houston
-
-
Vermont
-
Bennington, Vermont, United States, 05201
- Memory Clinic Inc
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Early Alzheimer's disease (AD): Gradual and progressive subjective decline in the participant's cognition over at least the past 6 months, as reported by the participant and informant (study partner) and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 and memory box score greater than or equal to (>=) 0.5 at screening
- Participants must have positive tau PET results
- Able to read and write and with a minimum 5 years of formal education as reported by participant and study partner at screening
- Have a designated study partner who has adequate literacy to participate and be judged to have high likelihood of completing the study with the participant
- Male participants must agree not to donate sperm for the purpose of reproduction during the study and up to 16 weeks after receiving the last dose of study intervention
Exclusion Criteria:
- Participants with CDR GS >=2 at predose baseline Clinical Dementia Rating (CDR) administration
- Participants who fulfill diagnostic criteria for Mild Cognitive Impairment (MCI) or dementia/mild or major neurocognitive disorder suspected to be due to any etiology other than AD (example, Parkinson's disease, cerebrovascular disease, normal pressure hydrocephalus, head injury, drug or alcohol abuse/dependence, anoxic brain injury, (Et cetera[etc])
- Geriatric Depression Scale (GDS) 30 score greater than (>) 12
- Hachinski Ischemic Scale (HIS) >4
- Has received medications that affect the central nervous system (CNS), except treatments for AD, for less than 2 months; that is, doses of chronic medications that effect the CNS should be stable for at least 2 months before the start of screening. If a participant has recently stopped a chronic medication that effects the CNS, he or she must have discontinued treatment at least 2 months before the start of screening. Chronic use of benzodiazepines is not permitted
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: JNJ-63733657 Low-dose
Participants will receive single dose of JNJ-63733657 low-dose administered by intravenous (IV) infusion every 4 weeks during the double-blind treatment period. Participants will have an option to continue with the long-term extension (LTE) phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period. |
JNJ-63733657 low or high dose will be administered by IV infusion. |
|
Experimental: JNJ-63733657 High-dose
Participants will receive single dose of JNJ-63733657 high-dose administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period. |
JNJ-63733657 low or high dose will be administered by IV infusion. |
|
Placebo Comparator: Placebo
Participants will receive single dose of matching placebo to JNJ-63733657 administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will be re-randomized in a 1:1 ratio to receive either JNJ-63733657 low-dose or JNJ-63733657 high-dose during the LTE treatment period. |
Placebo matching to JNJ-63733657 will be administered by IV infusion. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Double-blind (DB) Treatment Period: Change From Baseline in Integrated Alzheimer's Disease Rating Scale for Mild Cognitive Impairment (iADRS-MCI) Total Score at Week 104
Time Frame: Baseline (Day 1), Week 104
|
The iADRS-MCI was a composite measure of cognition and function. It was originally developed as a combination of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) 14-item cognition subscale and the instrumental activities of daily living (ADL) items from the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scale. It was calculated as a linear combination of total scores of the 2 individual components. The iADRS-MCI total score was derived as a combination of the ADAS-Cog13 total score (ranging from 0 to 85, with higher scores indicating worse cognitive performance) and the ADCS-ADL-MCI total score (ranging from 0 to 53, with lower scores indicating worse daily function). Therefore, the iADRS-MCI total score was calculated as [-1(ADAS-Cog13 score)+85] + ADCS-ADL-MCI score, ranging from 0 to 138, with lower scores indicating worse performance. |
Baseline (Day 1), Week 104
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Double-blind (DB) Treatment Period: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive, 13-item Version (ADAS-Cog13) Total Score at Week 104
Time Frame: Baseline (Day 1), Week 104
|
The ADAS-Cog was a rater administered instrument that was designed to assess the severity of dysfunction in cognition characteristic of persons with Alzheimer's Disease (AD). The ADAS-Cog13 item scale includes all items from the original ADAS-Cog11 (consisting of 11 tasks measuring the disturbances of memory, language, praxis, attention, and other cognitive abilities, often referred to as the core symptoms of AD) in addition of number cancellation task and a delayed free recall task, for a total of 85 points (0 to 85), with higher scores indicating worse cognitive performance. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living for Mild Cognitive Impairment (ADCS-ADL-MCI) Total Score at Week 104
Time Frame: Baseline (Day 1), Week 104
|
The ADCS-ADL-MCI was a functional measure based on information provided by the study partner that describes the performance of participants in several activities of daily living. The ADCS-ADL-MCI scale consists of 17 instrumental items (example; shopping, preparing meals, using household appliances, etc) and 1 basic item (getting dressed). The ADCS-ADL-MCI scale version used in this study comprises 24 items of which 18 items are used for the standard analysis. The total score ranges from 0 to 53 with higher scores indicating less impairment. A positive change from baseline indicates healthy functioning while a negative change from baseline indicates a decline in independent functioning. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at Week 88
Time Frame: Baseline (Day 1), Week 88
|
The RBANS was a battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that are divided into 5 RBANS indices: Immediate memory (list learning and story memory), visuospatial/constructional (figure copy and line orientation), language (picture naming and semantic fluency), attention (digit span and coding) and delayed memory (list recall, list recognition, story recall, and figure recall). Index scores are expressed as an age-adjusted standard score with a normal mean of 100 and an standard deviation (SD) of 15. Sum of index scores was the sum of the 5 index scores, and the Sum of Index Scores was converted to an RBANS total scale index score via a mapping table. The RBANS total scale Index score was a norm-based t-score, based on a distribution with a mean of 100 and an SD of 15. Scores range from 40 to 160. Higher scores indicated better performance. |
Baseline (Day 1), Week 88
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Each of the 5 Individuals RBANS Indices at Week 88
Time Frame: Baseline (Day 1), Week 88
|
The RBANS was a battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that are divided into 5 RBANS indices: Immediate memory (list learning and story memory), visuospatial/constructional (figure copy and line orientation), language (picture naming and semantic fluency), attention (digit span and coding) and delayed memory (list recall, list recognition, story recall, and figure recall). Index scores are expressed as an age-adjusted standard score with a normal mean of 100 and an standard deviation (SD) of 15. Sum of index scores was the sum of the 5 index scores, and the sum of index scores was converted to an RBANS total scale index score via a mapping table. The RBANS Total Scale Index Score was a norm-based t-score, based on a distribution with a mean of 100 and an SD of 15. Scores range from 40 to 160 each of the index scores. Higher scores indicated better performance. |
Baseline (Day 1), Week 88
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Each of the 12 Subtests Comprising the RBANS at Week 88
Time Frame: Baseline (Day 1), Week 88
|
The RBANS was a battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that are divided into 5 RBANS indices: Immediate memory (list learning [0-40] and story memory [0-24]), visuospatial/constructional (figure copy [0-20] and line orientation [0-20]), language (picture naming [0-10] and semantic fluency [0-40]), attention (digit span [0-16] and coding [0-89]) and delayed memory (list recall [0-10], list recognition [0-20], story recall [0-12], and figure recall [0-20]). Index scores are expressed as an age-adjusted standard score with a normal mean of 100 and an SD of 15. Sum of index scores was the sum of the 5 index scores, and the Sum of Index Scores was converted to an RBANS total scale index score via a mapping table. Scores range from 40 to 160. Higher scores indicated better performance. |
Baseline (Day 1), Week 88
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at Week 104
Time Frame: Baseline (Day 1), Week 104
|
The CDR was a subjectively rated outcome measure that serves as a global clinical staging instrument. Six domains were assessed and then synthesized to assign a Global CDR score. It included 3 cognitive and 3 functional domains: 1) memory, 2) orientation, 3) judgment and problem solving, 4) involvement in community affairs, 5) home and hobbies, and 6) personal care based on the CDR interview. The CDR was scored 2 ways yielding a global CDR score (CDR-GS and CDR-SB). CDR was an ordinal parameter (scale 0 [least impairment] to 3 [severe impairment]). The CDR-SB was the sum of the 6 domains which ranged from 0 (least impairment) to 18 (severe impairment). Higher scores indicated worse disease state. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Week 104
Time Frame: Baseline (Day 1), Week 104
|
The NPI was a measure of psychobehavioral disturbances, assessing the frequency and severity of disturbances in 12 domains, based on a caregiver interview. For each domain, there was also an assessment of caregiver burden. Frequency for each domain was rated on a 4-point scale (from 1=rarely to 4=very often) and severity on a 3-point scale (from 1=mild to 3=severe), with the score for each domain being the product of the frequency and severity scores, such that each domain was scored from 1 to 12. The NPI total score was the sum of the 12 domain scores, ranged from 0 (best) to 144 (worst). Higher score indicated worst psychobehavior. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Percentage of Participants With Progression From Clinical Dementia Rating-Global Score (CDR-GS) 0 to 0.5 or Higher, 0.5 to 1 or Higher, and 1 to 2 or Higher
Time Frame: From baseline (Day 1) up to Week 104
|
Percentage of participants with progression from CDR-GS 0 to 0.5 or higher, 0.5 to 1 or higher, and 1 to 2 or higher was reported. The CDR was a subjectively rated outcome measure that serves as a global clinical staging instrument. Six domains were assessed and then synthesized to assign a Global CDR score. It included 3 cognitive and 3 functional domains: (1) memory, (2) orientation, (3) judgment and problem solving, (4) involvement in community affairs, (5) home and hobbies, and (6) personal care based on the CDR interview. CDR was scored 2 ways yielding a global CDR score (CDR-GS and CDR-SB). CDR was an ordinal parameter (scale 0 [least impairment] to 3 [severe impairment]). The CDR-GS was derived based on an algorithm and was scored of 0 (normal), 0.5 (very mild dementia), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia). Score ranges from 0 to 3 and a high score on CDR-GS indicated a high disease severity. |
From baseline (Day 1) up to Week 104
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Brain Tau Burden as Measured by Tau Positron Emission Tomography (PET) at Week 104
Time Frame: Baseline (Day 1), Week 104
|
Change from baseline in brain tau burden (tau naive composite Region of interest [ROI] standardized uptake value ratio [SUVR], cerebral cortex ROI SUVR, meta temporal ROI SUVR, spatial progression of tauopathy [SPOT] volume over cerebral cortex ROI) as measured by tau PET was reported. For tau naive ROI method, tau PET brain scans were assessed to measure change in SUVR over regions without evidence of tau burden at baseline (that is, within 1 standard deviation of a cognitively normal amyloid negative reference population). For SPOT method, tau PET brain scans were assessed to quantify extent of spread of tau by measuring difference in volume of elevated tau PET burden (defined as exceeding an SUVR threshold of 1.2) in cerebral cortex brain region at follow up versus that at baseline. Tau PET brain scans were assessed to measure spread of tau tangles using SUVR in cerebral cortex, meta temporal brain region, respectively. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Cerebrospinal Fluid (CSF) Concentrations of Total, Free, and Bound p217+Tau Fragments at Week 104
Time Frame: Baseline (Day 1), Week 104
|
Change from baseline in CSF concentration of total, free, and bound p27+tau fragments at Week 104 was reported. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Cerebrospinal Fluid (CSF) Concentrations of JNJ-63733657
Time Frame: Weeks 52, 104, and 208
|
CSF concentration of JNJ-63733657 was reported. |
Weeks 52, 104, and 208
|
|
Double-blind (DB) Treatment Period: Serum Concentrations of JNJ-63733657
Time Frame: Baseline (Day 1), Weeks 4, 8, 12, 16, 20, 24, 36, 52, 76, 104, 128, 156, and 180
|
Serum concentration of JNJ-63733657 was reported. |
Baseline (Day 1), Weeks 4, 8, 12, 16, 20, 24, 36, 52, 76, 104, 128, 156, and 180
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent JNJ-63733657 Antidrug Antibodies (ADAs) in Serum
Time Frame: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
Number of participants with treatment-emergent JNJ-63733657 ADA in serum was reported. Any ADAs occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. Participants with treatment-emergent antibodies to JNJ-63733657 included participants with treatment-induced antibodies to JNJ-63733657 and treatment-boosted antibodies to JNJ- 63733657. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time Frame: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Any AE occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Time Frame: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Serious adverse event (SAE) was any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. Any SAE occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)
Time Frame: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Treatment-emergent AESIs were collected in the eCRF and examined separately, grouped in the following categories including: hepatobiliary disorders/Liver enzyme abnormality, and Infusion-related reactions. Any AESI occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants Who Discontinued Study Treatment Due to AEs
Time Frame: Baseline (Day 1) up to Week 232
|
Number of participants who discontinued the study treatment due to AE was reported. |
Baseline (Day 1) up to Week 232
|
|
Double-blind (DB) Treatment Period: Change From Baseline in 12-lead Electrocardiogram (ECG) Parameter: ECG Mean Heart Rate Supine
Time Frame: Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
|
Change from baseline in 12-lead ECG parameter (ECG mean heart rate supine) was reported. |
Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
|
|
Double-blind (DB) Treatment Period: Change From Baseline in 12-lead ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcB Interval, QTcF Interval, QTcL Interval, and RR Interval
Time Frame: Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
|
Change from baseline in 12-lead ECG parameter (PR interval, QRS duration, QT interval, QTcB interval, QTcF interval, QTcL interval and RR interval) was reported. |
Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormalities in Laboratory Parameters
Time Frame: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
Number of participants with treatment-emergent abnormalities in laboratory parameters (hematology, chemistry and urinalysis) were reported. Laboratory abnormalities meeting with lower limit of the normal range (LLN) and upper limit of the normal range (ULN) was reported. Any laboratory abnormalities occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormal Findings in Neurological Examination
Time Frame: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
Number of participants with treatment-emergent abnormal findings in neurological examination (mental state, cranial nerves, motor ability: strength, tone, involuntary movements, coordination: finger-to-nose, gai, postural reflexes, sensation: proprioception, cold, light touch, deep tendon reflexes) was reported. Abnormalities in neurological examination was determined by the investigator. Any neurological abnormalities occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormal Findings in Physical Examination
Time Frame: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
Number of participants with treatment-emergent abnormal findings in physical examination (general appearance, skin, eye, ear, nose, throat, heart, head, neck, thyroid, chest, lung, abdomen, musculoskeletal, breast, neurological) was reported. Abnormal findings in physical examination was determined by the investigator. Any physical abnormalities occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Potentially Clinically Significant Vital Signs
Time Frame: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
Number of participants with treatment-emergent potentially clinically significant vital signs including systolic blood pressure (standing and supine: less than (<) 90 millimeters of mercury (mmHg) and greater than (>) 180 mmHg), diastolic blood pressure (standing and supine: <50 mmHg and >105 mmHg), pulse (<45 bpm to >120 bpm), temperature (<35 degree Celsius and >38 degree Celsius) and weight (decrease of >=10% relative to baseline and increase of >=10% relative to baseline) were reported. Any clinically significant vital sign occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Brain Magnetic Resonance Imaging (MRI) Safety Findings
Time Frame: From Day 1 up to Week 245
|
Number of participants with brain MRI safety findings was reported. MRI safety-related observations from the central imaging vendor including vasogenic edema, cerebral macrohemorrhages, cerebral superficial siderosis and other findings was reported. |
From Day 1 up to Week 245
|
|
Double-blind (DB) Treatment Period: Number of Participants With Shift From Baseline in Suicidal Ideation or Suicidal Behavior as Assessed by Columbia Suicidality Severity Rating Scale (C-SSRS)
Time Frame: Baseline (Day 1) up to Week 245
|
C-SSRS was a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (suicidal ideation without plan and intent), 4 (suicidal ideation intent to act without plan), and 5 (suicidal ideation with plan and intent). Suicidal behavior was classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt [non-fatal]), and 10 (suicide). Total score from 10 categories was summarized into 3 categories: No suicidal ideation or behavior(0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranged from 0 to 10. Higher scores indicated more severe suicidal ideation and behavior. |
Baseline (Day 1) up to Week 245
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CR108832
- 2020-000116-30 (EudraCT Number)
- 63733657ALZ2002 (Other Identifier: Janssen Research & Development, LLC)
- 2022-501188-42-00 (Registry Identifier: EUCT number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.